EU - Viracta's Nana-val granted ODD by EC in DLBCL

Viracta has announced that the European Commission (EC) has granted an orphan drug designation (ODD) to its all-oral combination product candidate, Nana-val (nanatinostat and valganciclovir), for the treatment of diffuse large B-cell lymphoma (DLBCL). The EC previously granted ODD to Nana-val for the treatment of peripheral T-cell lymphoma.

As a reminder, Nana-val was previously granted ODD by the U.S. Food and Drug Administration for the treatment of T-cell lymphoma, post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and Epstein-Barr virus-positive (EBV⁺) DLBCL, not otherwise specified.

Reference link: Viracta press release